References
- DrossmanDAFunctional gastrointestinal disorders: history, pathophysiology, clinical features and Rome IVGastroenterology2016150612621279.e2
- ManningAPThompsonWGHeatonKWMorrisAFTowards positive diagnosis of the irritable bowelBr Med J197826138653654698649
- RubinGDe WitNMeineche-SchmidtVSeifertBHallNHunginPThe diagnosis of IBS in primary care: consensus development using nominal group techniqueFam Pract200623668769217062586
- ThompsonWGThe road to RomeGastroenterology200613051552155616678568
- LongstrethGFThompsonWGCheyWDHoughtonLAMearinFSpillerRCFunctional bowel disordersGastroenterology200613051480149116678561
- DrossmanDAHaslerWLRome IV – functional GI disorders: disorders of gut-brain interactionGastroenterology201615061257126127147121
- LacyBEMearinFChangLBowel disordersGastroenterology2016150613931407.e5
- LewisSJHeatonKWStool form scale as a useful guide to intestinal transit timeScand J Gastroenterol19973299209249299672
- LovellRMFordACGlobal prevalence of and risk factors for irritable bowel syndrome: a meta-analysisClin Gastroenterol Hepatol2012107712721.e422426087
- LovellRMFordACEffect of gender on prevalence of irritable bowel syndrome in the community: systematic review and meta-analysisAm J Gastroenterol20121077991100022613905
- HoughtonLAHeitkemperMCrowellMAge, gender and women’s health and the patientGastroenterology Epub2016215
- CanavanCWestJCardTThe epidemiology of irritable bowel syndromeClin Epidemiol20146718024523597
- HeidelbaughJJStelwagonMMillerSASheaEPCheyWDThe spectrum of constipation-predominant irritable bowel syndrome and chronic idiopathic constipation: US survey assessing symptoms, care seeking, and disease burdenAm J Gastroenterol2015110458058725781368
- NellesenDYeeKChawlaALewisBECarsonRTA systematic review of the economic and humanistic burden of illness in irritable bowel syndrome and chronic constipationJ Manag Care Pharm201319975576424156644
- HuliszDThe burden of illness of irritable bowel syndrome: current challenges and hope for the futureJ Manag Care Pharm200410429930915298528
- DoshiJACaiQBuonoJLEconomic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured populationJ Manag Care Spec Pharm201420438239024684643
- HunginAPMolloy-BlandMClaesRSystematic review: the perceptions, diagnosis and management of irritable bowel syndrome in primary care: a Rome Foundation working team reportAliment Pharmacol Ther201440101133114525230281
- HarknessEFHarringtonVHinderSGP perspectives of irritable bowel syndrome: an accepted illness, but management deviates from guidelines: a qualitative studyBMC Fam Pract2013149223805998
- KolarGJLockeGRWhat is the best way to identify and quantify irritable bowel syndrome?EmmanuelAQuigleyEMIrritable Bowel Syndrome: Diagnosis and Clinical ManagementHoboken (NJ)Blackwell20135167
- EngsbroALBegtrupLMKjeldsenJPatients suspected of irritable bowel syndrome: cross-sectional study exploring the sensitivity of Rome III criteria in primary careAm J Gastroenterol2013108697298023419383
- Van OudenhoveLLevyRLCrowellMDBiopsychosocial aspects of functional gastrointestinal disordersGastroenterology2016150613551367.e2
- BarbaraGFeinle-BissetCGhoshalUCThe intestinal microenvironment and functional gastrointestinal disordersGastroenterology2016150613051318.e8
- VannerSGreenwood-Van MeerveldBMaweGFundamentals of neurogastroenterology: basic scienceGastroenterology2016150612801291
- AdeyemoMASpiegelBMChangLMeta-analysis: do irritable bowel syndrome symptoms vary between men and women?Aliment Pharmacol Ther201032673875520662786
- OlafsdottirLBGudjonssonHJonsdottirHHBjörnssonEThjodleifssonBNatural history of irritable bowel syndrome in women and dysmenorrhea: a 10-year follow-up studyGastroenterol Res Pract2012201253420422474441
- IrvineAJCheyWDFordACScreening for celiac disease in irritable bowel syndrome: an updated systematic review and meta-analysisAm J Gastroenterol20171121657627753436
- HookwayCBucknerSCroslandPLongsonDIrritable bowel syndrome in adults in primary care: summary of updated NICE guidanceBMJ2015350h70125716701
- TazzymanSRichardsNTruemanARVitamin D associates with improved quality of life in participants with irritable bowel syndrome: outcomes from a pilot trialBMJ Open Gastroenterol201521e000052
- QuigleyEMFriedMGweeKAWorld Gastroenterology Organisation global guidelines: irritable bowel syndrome – a global perspectiveJ Clin Gastroenterol201650970471327623513
- PriorAMaxtonDGWhorwellPJAnorectal manometry in irritable bowel syndrome: differences between diarrhoea and constipation predominant subjectsGut19903144584622338274
- VannerSJDepewWTPatersonWGPredictive value of the Rome criteria for diagnosing the irritable bowel syndromeAm J Gastroenterol199994102912291710520844
- DrossmanDAThompsonWGThe irritable bowel syndrome: review and a graduated multicomponent treatment approachAnn Intern Med199211612 Pt 1100910161586090
- BallouSKeeferLPsychological Interventions for irritable bowel syndrome and inflammatory bowel diseasesClin Transl Gastroenterol201781e21428102860
- ChangFYIrritable bowel syndrome: the evolution of multi-dimensional looking and multidisciplinary treatmentsWorld J Gastroenterol201420102499251424627587
- LonshteynMChandarAFalck-YtterYLarge effects of a low FODMAPs diet in patients with irritable bowel syndrome: a systematic review and meta-analysisGastroenterology20141465 Suppl 1S535S536
- FaresjoAGrodzinskyEFoldeviMJohanssonSWallanderMAPatients with irritable bowel syndrome in primary care appear not to be heavy healthcare utilizersAliment Pharmacol Ther200623680781416556183
- DrossmanDAChangLKellowJCheyWDTackJWhiteheadWERome IV Functional Gastrointestinal Disorders for Primary Care and non-GI CliniciansRaleigh (NC)Rome Foundation2016
- WeinbergDSSmalleyWHeidelbaughJJSultanSAmerican Gastroenterological Association institute guideline on the pharmacological management of irritable bowel syndromeGastroenterology201414751146114825224526
- LacyBELevenickJMCrowellMDLinaclotide: a novel therapy for chronic constipation and constipation-predominant irritable bowel syndromeGastroenterol Hepatol (N Y)201281065366024683372
- BryantAPBusbyRWBartoliniWPLinaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tractLife Sci20108619–2076076520307554
- CamilleriMBuenoLAndresenVDe PontiFChoiMGLemboAPharmacological, pharmacokinetic, and pharmacogenomic aspects of functional gastrointestinal disordersGastroenterology2016150613191331.e20
- CastroJHarringtonAMHughesPALinaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cyclic guanosine 3’,5’-monophosphateGastroenterology2013145613341346e11123958540
- JohnstonJMKurtzCBMacdougallJELinaclotide improves abdominal pain and bowel habits in a phase IIB study of patients with irritable bowel syndrome with constipationGastroenterology2010139618771886.e220801122
- CheyWDLemboAJLavinsBJLinaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safetyAm J Gastroenterol2012107111702171222986437
- RaoSLemboAJShiffSJA 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipationAm J Gastroenterol2012107111714172522986440
- AtluriDKChandarAKBharuchaAEFalck-YtterYEffect of linaclotide in irritable bowel syndrome with constipation (IBS-C): a systematic review and meta-analysisNeurogastroenterol Motil201426449950924351035
- MacdougallJEJohnstonJMLavinsBJAn evaluation of the FDA responder endpoint for IBS-C clinical trials: analysis of data from linaclotide phase 3 clinical trialsNeurogastroenterol Motil201325648148623384406
- US Food and Drug AdministrationLinaclotide [prescribing information]2012 Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202811s000lbl.pdfAccessed September 16, 2017
- ReyEMearinFAlcedoJOptimizing the use of linaclotide in patients with constipation-predominant irritable bowel syndrome: an expert consensus reportAdv Ther201734358759828083815
- FisherMWalkerAFalquesMCost-effectiveness of linaclotide compared to antidepressants in the treatment of irritable bowel syndrome with constipation in ScotlandEur J Health Econ20161791091110026728984
- HuangHTaylorDCCarsonRTEconomic evaluation of linaclotide for the treatment of adult patients with irritable bowel syndrome with constipation in the United StatesJ Med Econ201518428329425333331
- FrancisconiCFSperberADFangXMulticultural aspects in functional gastrointestinal disorders (FGIDs)Gastroenterology2016150613441354.e2
- LadabaumUBoydEZhaoWKDiagnosis, comorbidities, and management of irritable bowel syndrome in patients in a large health maintenance organizationClin Gastroenterol Hepatol2012101374521871250
- WhiteheadWEPalssonOSLevyRRFeldADTurnerMVon KorffMComorbidity in irritable bowel syndromeAm J Gastroenterol2007102122767277617900326
- WhiteheadWEPalssonOJonesKRSystematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications?Gastroenterology200212241140115611910364
- KabraNNadkarniAPrevalence of depression and anxiety in irritable bowel syndrome: a clinic based study from IndiaIndian J Psychiatry2013551778023439939
- Fadgyas-StanculeteMBugaAMPopa-WagnerADumitrascuDLThe relationship between irritable bowel syndrome and psychiatric disorders: from molecular changes to clinical manifestationsJ Mol Psychiatry201421425408914
- ChapmanRWStanghelliniVGeraintMHalphenMRandomized clinical trial: macrogol/PEG 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndromeAm J Gastroenterol201310891508151523835436
- CheyWDKurlanderJEswaranSIrritable bowel syndrome: a clinical reviewJAMA2015313994995825734736